Logo-jcvtr

J Cardiovasc Thorac Res. 2019;11(4): 254-263. doi: 10.15171/jcvtr.2019.43
PMID: 31824606        PMCID: PMC6891044

Review Article

Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta-analysis of prospective cohort studies

Somayeh Tajik 1, Atieh Mirzababaei 1,2 * ORCID, Ehsan Ghaedi 3, Hamed Kord-Varkaneh 4 * , Khadijeh Mirzaei 1

Cited by CrossRef: 11

1- Yan L, Zhang X, Xu F, Fan Y, Ge B, Guo H, Li Z. Four-microRNA signature for detection of type 2 diabetes. WJCC. 2020;8(10):1923 [Crossref]
2- Llamosas-Falcón L, Rehm J, Bright S, Buckley C, Carr T, Kilian C, Lasserre A, Lemp J, Zhu Y, Probst C. The Relationship Between Alcohol Consumption, BMI, and Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis. 2023;46(11):2076 [Crossref]
3- Wei Y, Wang R, Wang J, Han X, Wang F, Zhang Z, Xu Y, Zhang X, Guo H, Yang H, Li X, He M. Transitions in Metabolic Health Status and Obesity Over Time and Risk of Diabetes: The Dongfeng–Tongji Cohort Study. 2023;108(8):2024 [Crossref]
4- Wang M, Ou Y, Yuan X, Zhu X, Niu B, Kang Z, Zhang B, Ahmed A, Xing G, Su H. Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors. World J Diabetes. 2024;15(1):53 [Crossref]
5- Zhang J, Xu Q, Lai F, Chen N, Lin M, Liu Y, Zhang W, Liu C, Wang S, Li Z. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. BMJ Open Diab Res Care. 2021;9(1):e002362 [Crossref]
6- Zhu X, Hu J, Guo H, Ji D, Yuan D, Li M, Yan T, Xue C, Ma H, Zhou X, Liu Y, Li Y, Sun K, Liu Y, Sun Z, Wang B. Effect of Metabolic Health and Obesity Phenotype on Risk of Diabetes Mellitus: A Population-Based Longitudinal Study. DMSO. 2021;Volume 14:3485 [Crossref]
7- Dragano N, Fernø J, Diéguez C, López M, Milbank E. Recent Updates on Obesity Treatments: Available Drugs and Future Directions. Neuroscience. 2020;437:215 [Crossref]
8- Lin B, Lin T, Lin C, Liao L, Chang T, Lu B, Chen K. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. 2021;84(6):606 [Crossref]
9- Dragano N, Fernø J, Diéguez C, López M, Milbank E. Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. Neuroscience. 2020;447:191 [Crossref]
10- Hoddy K, Axelrod C, Mey J, Hari A, Beyl R, Blair J, Dantas W, Kirwan J. Insulin resistance persists despite a metabolically healthy obesity phenotype. Obesity. 2022;30(1):39 [Crossref]
11- Ahmad M, Zawatia A. Current prospects of metabolically healthy obesity. Obesity Medicine. 2021;25:100361 [Crossref]
12- Ottosson F, Smith E, Ericson U, Brunkwall L, Orho-Melander M, Di Somma S, Antonini P, Nilsson P, Fernandez C, Melander O. Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality. 2022;45(5):1260 [Crossref]
13- de Medeiros W, Gomes A, Aguiar A, de Queiroz J, Bezerra I, da Silva-Maia J, Piuvezam G, Morais A. Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review. IJMS. 2024;25(9):4699 [Crossref]